Eltrom 50 mg (Tablet)

Unit Price: ৳ 900.00 (1 x 7: ৳ 6,300.00)
Strip Price: ৳ 6,300.00

Medicine Details

Category Details
Generic Eltrombopag olamine
Company Jenphar bangladesh ltd
Also available as
Eltrom 25 mg tablet

Title

  • Eltrombopag Olamine Tablets

Categories

  • Thrombopoietin (TPO) Receptor Agonist
  • Hematologic Medication
  • Oral Medication

Description

  • Eltrombopag is indicated for the treatment of thrombocytopenia in patients with persistent or chronic immune thrombocytopenia, hepatitis C infection, and severe aplastic anemia.
  • It is not indicated for the treatment of patients with myelodysplastic syndromes (MDS) or in combination with direct-acting antiviral agents used without interferon for the treatment of chronic hepatitis C infection.
  • Eltrombopag interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells finally leading to increased platelet production.
  • The route of administration is oral, and it can be taken with or without a meal low in calcium (<50 mg).
  • Dosage varies based on the condition being treated, age, ancestry, and hepatic impairment status.
  • It is contraindicated in patients with known hypersensitivity to eltrombopag or any components of this product.
  • The most common side effects include anemia, nausea, pyrexia, ALT increased, cough, fatigue, headache, and diarrhea.
  • It is not recommended during pregnancy or breastfeeding due to insufficient data available to assess any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.
  • In patients with chronic hepatitis C, Eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation. There is also an increased risk of death and progression of myelodysplastic syndromes to acute myeloid leukemia.

Dimensions

  • N/A

Color options

  • N/A

Functions

  • Stimulates platelet production
  • Treatment of thrombocytopenia
  • Oral administration for various conditions
  • Contraindicated in certain medical conditions

Materials

  • N/A

Technical specifications

  • Route of oral administration
  • Specific dosages for different conditions and patient demographics

Design elements

  • Small molecule thrombopoietin (TPO) receptor agonist

Usability features

  • N/A

Safety features

  • Contraindicated in patients with known hypersensitivity

Interaction

  • Take eltrombopag at least 2 hours before or 4 hours after any medications or products containing polyvalent cations such as antacids and mineral supplements.
  • Take eltrombopag at least 2 hours before or 4 hours after any calcium rich foods.

Precautions

  • Increased risk of hepatic decompensation in patients with chronic hepatitis C
  • Increased risk of death and progression of myelodysplastic syndromes to acute myeloid leukemia
  • Portal vein thrombosis has been reported in patients with chronic liver disease receiving eltrombopag. Monitor platelet counts regularly.

Age group

  • Adults
  • Pediatric Patients (6 years and older)
  • Pediatric Patients (1 to 5 years)

Dosage form

  • Oral tablets

Dosage strength

  • 25 mg
  • 50 mg
  • 75 mg
  • 100 mg
  • 150 mg

Administration route

  • Oral

Pregnancy category

  • Not recommended during pregnancy

Storage conditions

  • Store in a cool (below 25°C) and dry place protected from light. Keep away from the reach of children.

Patient instructions

  • Take with or without a meal low in calcium (<50 mg)
  • Avoid certain medications or products containing polyvalent cations close to the time of eltrombopag administration

Pharmacology

  • Small molecule thrombopoietin (TPO) receptor agonist
  • Interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells finally leading to increased platelet production.

Contraindications

  • Known hypersensitivity to eltrombopag or any components of this product
  • Not indicated for the treatment of patients with myelodysplastic syndromes (MDS) or in combination with direct-acting antiviral agents used without interferon for the treatment of chronic hepatitis C infection

Side effects

  • Anemia
  • Nausea
  • Pyrexia
  • ALT increased
  • Cough
  • Fatigue
  • Headache
  • Diarrhea

Pregnancy and lactation

  • Not recommended during pregnancy or breastfeeding due to insufficient data available

Precautions and warnings

  • Increased risk of hepatic decompensation in patients with chronic hepatitis C
  • Increased risk of death and progression of myelodysplastic syndromes to acute myeloid leukemia

Pediatric uses

  • Safety and efficacy in pediatric patients with thrombocytopenia have not been established.

Overdose effects

  • In the event of overdose, platelet counts may increase excessively and result in thrombotic or thromboembolic complications.

Drug classes

  • Haemostatic drugs

Related Brands